bioRxiv Science⌕ Search

Biology subjects

Marimuthu, A.

Publications and source records attributed to Marimuthu, A..

2 recordsLinked to original sources

p62/SQSTM1 selectively supports starvation-induced autophagy in N2a neuroblastoma cells

Autophagy is a critical cellular process that maintains homeostasis and enables adaptation to metabolic stress. The selective autophagy receptor p62/SQSTM1 has been implicated in multiple aspects of autophagy regulation; however, its specific contribution to basal versus stress-induced autophagic flux remains incompletely defined, particularly in neuronal cells. In this study, we investigated the role of p62 in regulating basal and starvation-induced autophagy using a CRISPR-Cas9-generated p62 knockout (p62-/-) neuroblastoma (N2a) cell model. Autophagic flux was quantified by measuring LC3-II accumulation in the presence and absence of the lysosomal inhibitor bafilomycin A1. Under nutrient-replete conditions, basal autophagic flux was comparable between wild-type and p62-deficient cells, indicating that p62 is dispensable for constitutive autophagy. In contrast, starvation robustly increased autophagic flux in wild-type cells but failed to do so in p62-/- cells, demonstrating a requirement for p62 in starvation-induced autophagy. Consistent with a stress-responsive role, p62 protein levels increased during starvation in wild-type cells under lysosomal inhibition, reflecting enhanced p62 expression rather than impaired degradation. Together, these findings reveal a context-dependent function for p62 in neuronal autophagy, whereby p62 is essential for mounting an effective autophagic response to nutrient deprivation but is not required for basal autophagic turnover.

cell biology↗

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic

Intravenous administration (IV) of antiviral monoclonal antibodies (mAbs) is challenging due to limited resources for performing infusions during an ongoing epidemic. An ebolavirus therapeutic administered via intramuscular (IM) injection would reduce these burdens and allow rapid treatment of exposed individuals during an outbreak. Here, we demonstrate how MBP134, a two mAb pan-ebolavirus cocktail, reverses the course of Sudan ebolavirus (SUDV/Gulu) disease with a single IV or IM dose in non-human primates (NHPs) as far as five days post-exposure. Furthermore, we investigated the utility of adding half-life extension mutations to the MBP134 mAbs, ultimately creating a half-life extended cocktail designated MBP431. MBP431 demonstrated an extended serum half-life in vivo and offered complete or significant protection with a single IM dose delivered as a post-exposure prophylactic (PEP) or therapeutic in NHPs challenged with EBOV. These results support the use of MBP431 as a rapidly deployable IM medical countermeasure against every known ebolavirus.

microbiology↗